VA/DoD GERD guideline (correction)
Executive Summary
Veteran's Affairs/Department of Defense draft guideline states both proton pump inhibitors and H2-antagonists can be used for initial treatment of gastroesophageal reflux disease. "The Pink Sheet" (1April 21, p. 15) incorrectly suggested that the guidelines consider the two drug classes to be equally effective. Both Johnson & Johnson/Eisai's Aciphex (rabeprazole) and TAP's Prevacid (lansoprazole) are included on the Basic Core Formulary...
You may also be interested in...
VA/DoD Guidelines Suggest PPIs, H2-Antagonists Work Equally Well For GERD
H2-antagonists and proton pump inhibitors work equally well for the initial treatment of gastroesophageal reflux disease, a 1draft guideline on clinical practice from the Departments of Defense and Veterans Affairs states
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.